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Ets-2 is a transcriptional activator that can be modu-
lated by ras-dependent phosphorylation. Evidence is
presented indicating that ets-2 can also act as a tran-
scriptional repressor. In the breast cancer cell line
MCF-7, exogenous ets-2 repressed the activity of a
BRCA1 promoter-luciferase reporter dependent on a
conserved ets-2-binding site in this promoter. Condi-
tional overproduction of ets-2 in MCF-7 cells resulted in
repression of endogenous BRCA1 mRNA expression. To
address the mechanism by which ets-2 could act as a
repressor, a biochemical approach was used to identify
proteins that interacted with the ets-2 pointed domain.
From this analysis, components of the mammalian SWI/
SNF chromatin remodeling complex were found to in-
teract with ets-2. Brg-1, the ATP-hydrolyzing component
of the SWI/SNF complex, along with the BAF57/p50 and
Ini1 subunits could be co-immunoprecipitated from
cells with ets-2. The pointed domain of ets-2 directly
interacted in vitro with the C-terminal region of Brg-1 in
a phosphorylation-dependent manner. The combination
of Brg-1 and ets-2 could repress the BRCA1 promoter
reporter in transfection assays. These results support a
role for ets-2 as a repressor and indicate that compo-
nents of the mammalian SNF/SWI complex are required
as co-repressors.
The ETS family, encompassing approximately 30 vertebrate
members, encodes for sequence-specific DNA-binding proteins
that are transcriptional activators and repressors (1). The fam-
ily is defined by a highly conserved DNA binding domain re-
ferred to as the ETS domain. However, the DNA-binding prop-
erties of these factors are similar and cannot entirely account
for the specificity required for the precise activation of target
genes that occurs during the diverse biological processes medi-
ated by individual family members. Modification of discrete
family members by signal transduction pathways provides an
additional mechanism to determine specificity (1).
For example, members of the ETS family of transcription
factors are important for mediating both transient and persis-
tent changes in gene expression patterns in response to ras-
signaling pathways (2–4). The ETS family member elk-1 and
related factors are directly phosphorylated by mitogen-acti-
vated protein kinases (MAPK),1 a modification required for the
activation of immediate early target genes like c-fos (2). Simi-
larly, phosphorylation of the ETS family members ets-1 and
ets-2 by ras-dependent pathways leads to persistent expression
of target genes including extracellular proteases such as uro-
kinase plasminogen activator (uPA) and stromelysin/MMP-3
(3, 4). Ets-1 and ets-2 are phosphorylated at a conserved resi-
due (threonine 38 and threonine 72, respectively) by the well
characterized ras-effector pathway, the Raf/MAPK pathway
(4–7). Additionally, the same residue in ets-2 can also be phos-
phorylated by another major ras-effector pathway, the phos-
phatidylinositol 3-kinase/Akt pathway (8).
Understanding at the molecular level how phosphorylation
modifies the activity of ets-1 and ets-2 will be critical for defin-
ing how these factors selectively regulate target genes. The key
phosphorylation event occurs within a region of ets-1 and ets-2
that is conserved through evolution with the Drosophila
pointed P2 protein, and has been termed the pointed domain (9,
10). Phosphorylation of the conserved threonine residue within
this region leads to an increased ability of ets-1 and ets-2 to
activate target promoters (3–7). Previous work indicated that
phosphorylation of ets-1 or ets-2 did not affect protein turnover,
nuclear localization, or intrinsic DNA binding activity of the
factors (3, 4, 7). In addition, the N-terminal region of ets-2
fused to the heterologous gal4 DNA binding domain is still
regulated by the ras/Erk pathway (11). The pointed domain
appears similar to domains in other transcription factors, for
example in the cAMP responsive enhancer-binding protein,
that are regulated by phosphorylation-dependent protein-pro-
tein interactions with transcription co-activators (12). Ets fac-
tors can also act as repressors of gene expression, and the
pointed homology domain has been implicated in this activity
in some family members (1). Thus, whereas ets-1 and ets-2
have been considered to be activators of gene expression, it is
possible that they also repress target gene expression.
Genetic and biochemical evidence demonstrate that the
products of the SWI/SNF genes, first defined in Saccharomyces
cerevisiae as co-activators of gene expression, form a complex
with the ability to remodel chromatin (13). The SWI/SNF com-
plex is conserved in mammals and can act as a co-activator for
steroid hormone receptors (13–16). The complex has ATP-de-
pendent chromatin remodeling activity and can alter the con-
formation of the nucleosome core in a reversible fashion (13,
14). The mammalian ATPase hydrolyzing subunit Brg-1 inter-
acts with the retinoblastoma tumor suppressor protein (Rb)
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(17). The Brg-1 remodeling complex is required for E2F/Rb-
mediated repression of gene expression (18, 19). Recently, ex-
periments performed in S. cerevisiae have definitively estab-
lished the ability of the ATPase-hydrolyzing subunit of the
complex (SNF2) to act as a co-repressor of gene expression (20).
Therefore, SWI/SNF appears to act as both co-activator and
co-repressor (20).
In the present report evidence is presented indicating that
ets-2 can repress the BRCA1 promoter, a promoter previously
reported to contain functional ets-binding sites (21–24), in the
breast cancer cell line MCF-7. Ets-2 can bind to the BRCA1
proximal promoter, and ets-2 co-expression results in repres-
sion of a BRCA1 promoter-luciferase in transient transfection
assays. Conditional overexpression of ets-2 in MCF-7 cells re-
sulted in repression of the endogenous BRCA1 promoter,
whereas expression of other targets, uPA and MMP3, were
stimulated by ets-2 overexpression. Biochemical evidence is
presented indicating that ets-2 physically interacted with dis-
crete sets of cellular proteins dependent on the phosphorylation
status of the factor. We show that components of the mamma-
lian SWI/SNF (mSWI/SNF) chromatin remodeling complex
comprised one set of proteins that interacted with unphospho-
rylated ets-2. The pointed homology region of ets-2 directly
interacted with the C-terminal region of Brg-1, the ATP-hydro-
lyzing component of the mammalian complex, in a phosphoryl-
ation-dependent manner in vitro. Co-expression of Brg-1 with
ets-2 resulted in repression of a stably integrated BRCA1 re-
porter gene in SW13 cells, a Brg-1 null cell line. These results
demonstrate that ets-2 can act as a repressor and that a chro-
matin remodeling complex is necessary for this activity.
EXPERIMENTAL PROCEDURES
Cell Lines—To generate the tetracycline-controlled inducible ets-2
MCF-7 cells, an influenza virus hemagglutinin (HA)-epitope tagged
version of wild-type ets-2 (3) was cloned into the tetracycline operator-
expression vector, pUHD10-3 (25), to generate pUHD10-3/HA-ets-2.
The MCF-7/Tet-off cell line (Clontech) was transfected with pUHD10-
3/HA-ets-2 to establish stable expression cell lines that can be induced
to express HA-ets-2. Transfections were done using LipofectAMINE
Plus (Invitrogen, Carlsbad, CA) as described previously (26). The tet-
racycline-controlled inducible ets-2 MCF-7 cells were grown in Dulbec-
co’s modified Eagle’s medium (DMEM) without phenol red with 10%
charcoal-treated fetal bovine serum and 1 g/ml tetracycline (Sigma).
To induce ets-2 expression, adherent cells were washed 3 times with
phosphate-buffered saline and then re-fed with 10% charcoal-treated
fetal bovine serum/DMEM without tetracycline.
For generating stable cell lines expressing ets-2 Ala-72 protein, NIH
3T3 cells were transfected with the HA-tagged version of ets-2 Ala-72 by
the calcium phosphate method as described (3), and hygromycin-resist-
ant clones were selected in 200 units/ml hygromycin (Calbiochem, Inc.)
and analyzed by Western blotting. Cells were grown in DMEM with
10% calf serum containing 100 units/ml hygromycin. For metabolic
labeling of cellular proteins with [35S]methionine, cells were placed in
DMEM that lacked both serum and methionine for 45 min, then incu-
bated with DMEM containing 90 Ci/ml [35S]methionine (1200 Ci/
mmol; ICN, Irvine, CA) for 2 h.
Human carcinoma SW13 cells were obtained from American Type
Culture Collection (Bethesda, MD) and cultured in DMEM plus 5%
bovine calf serum. SW13 cells that contained stably integrated BRCA1
promoter-luciferase reporter were generated by the co-transfection of 3
g of BRCA1-luciferase plasmid and 1 g of a neomycin-resistance
vector using LipofectAMINE Plus (Invitrogen). 48 h after transfection,
cells were selected with G418 (400 g/ml, Invitrogen) and media was
changed every 3 days. 14 days after selection, there were about 100
colonies on the dish. The cells were pooled and cultured with 200 g/ml
G418 and used for subsequent experiments.
Plasmids, DNA Transfections, and Northern Blots—The vector used
for expression of the HA-tagged versions of ets-2 and ets-2 Ala-72
proteins were previously described (3, 5). The expression vectors for
Brg-1 and Brg-1 K798R were previously described (16). The luciferase
reporters for the human BRCA1 (21), and murine MMP14/MT1-MMP
(27) promoters were kindly provided by Ellen Soloman (Guy’s Hospital,
London) and Joseph Madri (Yale University), respectively. The BRCA1
promoter with the ets-site double-point mutation CGTAAGAGT was
constructed by site-directed PCR mutagenesis as previously described
(3). The mutation was verified by sequencing.
Transient transfections in MCF7 or SW13 cells were performed by
the calcium phosphate method as described (3, 16). For the transient
assays either a Rous sarcoma virus--galactosidase (MCF-7 cells) or an
expression vector for Renilla luciferase (pRL-CMV, Promega, SW13
cells) was included as an internal control for transfection efficiency (0.1
g/DNA precipitate). Relative luciferase activity is equal to (raw lucif-
erase activity)/(raw activity of the internal control  the protein con-
centration of the extract) (3). Fold-repression is the ratio of relative
luciferase activity for the BRCA1-luciferase reporter alone (with empty
expression vectors) to the activity in the presence of ets-2, Brg-1, or the
combination of both ets-2 and Brg-1, as indicated in the figure legends.
The SW13 cells containing the stably integrated BRCA1 promoter
reporter were transfected using LipofectAMINE Plus (Invitrogen).
Brg-1 and ets-2 expression plasmids (see Fig. 7B) were cotransfected
with 0.5 g of a puromycin-resistant expression vector, pBABE-puro-
mycin (6). 36 h after transfection, cells were selected with 4 g/ml
puromycin and subsequently harvested 36 h after the initial selection.
Luciferase activity was adjusted by cell lysate protein concentration.
RNA was isolated and analyzed by Northern blotting as previously
described (5). Levels of RNA expression were quantified using a Amer-
sham Biosciences PhosphorImager.
Immune Reagents and Analysis—The antibodies specific for ets-2
and phosphorylated ets-2 (pT72-ets-2) have been previously described
(6). The anti-HA antibody was purchased from Babco, Inc. (Richmond,
CA). Polyclonal anti-rabbit antibodies specific for Brg-1 and Brm-1 were
gifts from Said Sif (Ohio State University), BAF57/p50 from Gerry
Crabtree (Stanford University), and Ini1 from Anthony Imbalzano
(University of Massachusetts).
For standard immunoprecipitations, 2.5–3  106 cells were placed in
500 l of lysis buffer consisting of 50 mM Tris-Cl, pH 7.4, 150 mM NaCl,
3 mM MgCl2, and 1% Nonidet P-40. For more stringent analysis, the
same buffer was used except that it contained 500 mM NaCl and 0.5%
deoxycholate in addition to 1% Nonidet P-40. The buffer contained a
mixture of protease and phosphatase inhibitors that was previously
described (5, 6). The pre-cleared cell lysates were incubated with spe-
cific antibody (2–4 g) and 20 l of a 50% slurry of protein-G beads
(Amersham Biosciences) overnight at 4 °C. The immunoprecipitates
were washed 4 times in lysis buffer and analyzed by SDS-PAGE.
Affinity Chromatography and Protein Interaction Assays—Recombi-
nant ets-2 protein corresponding to the pointed homology region (amino
acids 60–167) was prepared as described (5, 6) and covalently linked to
Affi-Gel 10 beads (10 mg of ets-2/ml of beads; Bio-Rad). The ets-2
column was phosphorylated in a reaction that contained 10 l of ets-2
affinity column, 30 l of kinase buffer (30 mM Hepes, pH 7.2, 20 mM
MgCl2, 2 mM dithiothreitol), 100 M ATP, 10 Ci of [-
32P]ATP (500
Ci/mmol, PerkinElmer Life Sciences), and 5 l of activated recombinant
MAPK p42 (Upstate Biotechnology, Lake Placid, NY). Either the un-
phosphorylated or the phosphorylated ets-2 affinity columns were in-
cubated with cell extracts prepared in lysis buffer as above for 16 h at
4 °C. Washing procedures and analysis were performed as for the im-
munoprecipitations above.
For direct protein interaction assays, a portion of Brg-1 correspond-
ing to amino acids 1108–1686 at the C-terminal of the protein (17) were
expressed as a GST fusion protein in Escherichia coli, and 1 g of fusion
protein was immobilized using glutathione beads (Amersham Bio-
sciences). The beads were incubated with 1 g of the recombinant ets-2
pointed domain that was unphosphorylated, or phosphorylated by re-
combinant MAPK p42 in a reaction that contained 10 Ci of [-32P]ATP
but no cold ATP (see above for details of the kinase reaction). Beads and
ets-2 protein were incubated in lysis buffer for 16 h at 4 °C. Beads were
washed and the material bound analyzed by Western blotting using the
ets-2 specific antibody, or for 32P-labeled protein by autoradiography
and phosphorimaging.
Western analysis was performed as previously described (5, 6). A
Lumi-Imager (Roche Diagnostics) was used for quantification of chemi-
luminescent signals. For estimation of ets-2 concentration, standard
curves for both ets-2 antibodies were prepared using recombinant pro-
tein corresponding to the ets-2 pointed domain that was phosphorylated
with MAPK p42 as described above.
Electrophoretic Mobility Shift Assays—Recombinant ets-2 corre-
sponding to the DNA binding domain (amino acids 334–466) was pro-
duced using the pGEX expression vector system and purified by gluta-
thione-Sepharose chromatography (Amersham Biosciences) as
previously described (28). Purified protein was used in the electro-
phoretic mobility shift assays using standard conditions as previously
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described (28). Double stranded oligonucleotides were end-labeled with
polynucleotide kinase. The sequences of the oligonucleotides used were
(sense strand) (BRCA1 oligos correspond to 208 to 182 relative to
the ATG): BRCA1 wild-type, 5-GGTAGAATTCTTCCTCTTCCGTCTC-
TTGG; BRCA1 M1, 5-GGTAGAATTCTTACTCTTCCGTCTCTTGG;
BRCA1 M2, 5-GGTAGAATTCTTCCTCTTACGTCTCTTGG; and
BRCA1 M1  M2, 5-GGTAGAATTCTTACTCTTACGTCTCTTGG. A
Amersham Biosciences PhosphorImager was used to quantify the
amount of protein-DNA complex formed.
RESULTS
Expression of ets-2 Correlates with Expression of ets-2 Target
Genes in Breast Cancer Cells—Previous work demonstrated
that expression of phosphorylated ets-2 correlates with a more
invasive, mesenchymal phenotype in both ovarian and prostate
cancer tumor cell lines (29, 30). To determine whether a similar
correlation was detected in breast cancer cell lines, we studied
expression of ets-2 and est-2 target genes in MCF-7 cells, an
estrogen receptor-positive non-invasive cell line, and in
MDA231 cells, representative of invasive breast tumor cell
lines (Fig. 1, A and B).
Western analysis of these two cell lines indicated that ets-2
was expressed at 10-fold higher levels in MDA231 cells than
in MCF-7 (Fig. 1A). Furthermore, the pT72 phosphorylated,
activated form of ets-2 could be detected in MDA231 cells but
not MCF-7 cells, as assayed using a pT72 ets-2 phospho-specific
antibody (5). Similar results were observed if ets-2 were first
immunoprecipitated from these two cell lines using the non-
phosphodiscriminating antibody, then analyzed by Western
analysis using the same antibody or the pT72 ets-2 antibody
(Fig. 1B, lanes 3 and 4, respectively). From these Western blots,
we estimated that 40–50% of ets-2 was phosphorylated at
position Thr-72 in MDA231 (see “Experimental Procedures”).
Correlating with phospho-ets-2 expression, the mRNA ex-
pression levels for three known ets-2 target genes, uPA (3, 28),
MMP3/stromelysin (31), and bcl-X (8, 32), were all higher levels
in MDA231 cells versus MCF-7 cells (Fig. 1C). Additionally, the
expression of another metalloprotease implicated in mammary
tumorigenesis MMP14/MMP-MT1 (27, 33, 34) was higher in
MDA231 cells than in MCF-7. MMP14 expression is reported to
be increased by ras signaling pathways (35), and the proximal
promoter for the mouse and human genes contain a consensus
ets-like site that is related to sites found in other ets-regulated
genes (Fig. 1D). Interestingly, the expression of ets-2 mRNA is
identical in MCF-7 and MDA231 cells, indicating that differ-
ences in ets protein expression between the two cell lines (see
Fig. 1, A and B) are because of a post-transcriptional regulatory
mechanism.
In contrast to the known ets-2 target genes, the expression of
tumor suppressor BRCA1 was 5-fold lower in MDA231 in
comparison to MCF-7 (Fig. 1C). The BRCA1  promoter, the
predominant promoter active in breast cells (36), also contains
a consensus ets-binding site conserved in both mouse and hu-
man promoters (21–24) (Fig. 1D). Thus, the expression of ets-2
protein and BRCA1 mRNA were inversely correlated in MCF-7
and MDA231 cells.
Ets-2 Binds to the BRCA1 Promoter and Represses BRCA1
Promoter Activity in MCF-7 Cells—To test the hypothesis that
ets-2 might repress BRCA1 expression, we first performed elec-
trophoretic mobility shift assay analysis to determine whether
ets-2 could bind to the ets-consensus site in the BRCA1 pro-
moter (Fig. 2A). Recombinant ets-2 bound to the BRCA1 oligo-
nucleotides containing the wild-type ets-binding site (ACG-
GAAGAGG, wild-type). However, 10-fold lower levels of ets-
2DNA complex was formed when the consensus site was
mutated by one base outside of the GGA core (ACGGAAGAGT,
M2). Mutation of the G residue in the ets core motif (ACGTA-
GAGG, M1), or a mutation of both G residues (ACGTAAGAGT,
M1  M2) ablated ets-2 recognition of the BRCA1 sequence
(Fig. 2A). These mutated oligonucleotides also failed to compete
effectively for binding to wild-type sequence in competition
assays (data not shown).
To determine whether ets-2 binding to the BRCA1 promoter
had functional significance, transient transfections were per-
formed in MCF-7 using BRCA1 and MMP14 promoter-lucif-
erase reporters. The BRCA1 promoter was highly active in
FIG. 1. Expression of phosphorylated ets-2 correlates with expression of target genes in the breast cancer cell lines MCF-7 and
MDA231. A, nuclear extracts from MCF-7 and MDA231 breast cancer cells were analyzed by SDS-PAGE, followed by Western blotting with the
anti-pT72 ets-2 (top panel). The same membrane as in the top panel was reprobed with a pan-ets-2 antibody (middle panel). Blot was reprobed with
antibody specific for the ets factor elf-1 as a loading control (bottom panel). The arrows indicate the position of ets-2. B, ets-2 was immunopre-
cipitated from MCF-7 (lane 3) and MDA231 (lane 4) cells using the non-phosphodiscriminating anti-ets-2 antibody. The immunoprecipitate was
analyzed by Western blotting using the same two antibodies used in panel A, as indicated in the figure. Lanes 1 and 2, preimmune ets-2 antiserum
was used for control immunoprecipitations from MCF-7 and MDA231, respectively. Arrows indicate the position of ets-2. The unlabeled band
present in each lane is immunoglobulin heavy chain. C, mRNA expression of ets-2 target genes in MCF-7 (lane 1) and MDA231 (lane 2). Total RNA
was prepared and analyzed by Northern blotting (10 g per lane) with uPA (first panel), MMP3/stromelysin (second panel), bcl-x (third panel),
MMP14 (fourth panel), BRCA1 (fifth panel), and ets-2 (sixth panel) probes utilized as indicated. Note that there are two ets-2 mRNA isoforms of
2.2 and 4.5 kb that differ in the 3 non-coding region. The blot was reprobed with a -actin probe (seventh panel) as a control for sample loading.
D, comparison of the target gene promoter sequences encompassing the ets-2-binding site. uPA (GenBankTM number X02419), MMP3 (GenBankTM
number U43511), bcl-x (GenBankTM number D30746), MMP14 (GenBankTM number AF158733), and BRCA1 (GenBankTM number U37574)
sequences are displayed. Also shown is the consensus sequence for an ets-1/ets-2-binding site (1).
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MCF-7 cells, but co-transfection of an ets-2 expression vector
resulted in a concentration-dependent repression of BRCA1
promoter activity, with a maximum repression of 10-fold ob-
served (Fig. 2B). In contrast, MMP14 promoter activity was low
in MCF-7 cells, and ets-2 co-expression stimulated MMP14
promoter activity by 12-fold in MCF-7 cells (Fig. 2B). When a
uPA promoter reporter was tested, results were similar to
those observed for the MMP14 promoter (data not shown).
To demonstrate whether ets-2 repression of BRCA1 pro-
moter activity required a functional ets-binding site, a BRCA1
promoter luciferase reporter with either a wild-type ets-bind-
ing site (ACGGAAGAGG) or a mutated ets-binding site (ACG-
TAAGAGT, M1  M2) were studied by transient transfection
in MCF-7 cells. Titration of ets-2 expression vector resulted in
a concentration-dependent repression of the wild-type BRCA1
promoter with a maximum repression of 10-fold observed, as
above. However, ets-2 was not able to repress activity of the
mutated BRCA1 promoter, indicating that the ets-binding site
is necessary for ets-2-mediated repression (Fig. 2C).
Previous work has demonstrated that the ets-2 transactiva-
tion potential is enhanced by phosphorylation at position
Thr-72 (3, 4, 7). To determine the role of residue Thr-72 in ets-2
activity in the transient assays in MCF-7 cells, we studied the
effect of co-transfection of a vector encoding the ets-2 T72A
mutation with both MMP14 and BRCA1 reporters (Fig. 2D). In
this analysis, MMP14 promoter activity was activated 2-fold
in the assays, and this activation was not dose dependent,
results that are consistent with what was observed with ets-2
T72A in NIH 3T3 fibroblasts (3). In contrast, ets-2 T72A re-
pressed the activity of the BRCA1 promoter in the same way as
ets-2 Thr-72 (Fig. 2D). These results indicate that an intact
Thr-72 site is required for transactivation of MMP14 and sim-
ilar targets, but not for repression of BRCA1.
Ets-2 Overexpression in MCF-7 Cells Inhibits BRCA1 Expres-
sion and Increases uPA and MMP3 Expression—To test
whether expression of exogenous ets-2 would affect the expres-
sion of the endogenous BRCA1 gene in MCF-7 cells, we con-
structed MCF-7 cell lines that conditionally express an HA
epitope-tagged ets-2. Conditional expression of ets-2 was ac-
complished by putting the gene under the control of the tetra-
cycline operator and tetracycline-VP16 activator, such that
ets-2 was expressed when tetracycline was removed from the
FIG. 2. Ets-2 binds to the BRCA1 promoters and represses BRCA1 promoter activity in MCF-7 cells. A, electrophoretic mobility shift
analysis with recombinant ets-2. The wild-type BRCA1 sequence (208 to 182 relative to the ATG) along with nucleotides mutated (shown by
asterisk) are represented above the gel. Wild-type BRCA1 (lane 1), mutated BRCA1 oligonucleotides M2 (lane 3), M1 (lane 5), and M1  M2 (lane
7) were end-labeled with 32P and incubated with 1 g of recombinant ets-2 protein, as indicated. Probes incubated without recombinant protein
were included in even numbered lanes (WT, M2, M1, and M1 M2 in lanes 2–8, respectively). B, MCF-7 cells were transfected with 5 g of human
BRCA1 or mouse MMP14 luciferase reporters and 100 ng of Rous sarcoma virus--galactosidase reporter (an internal control). Either empty
expression vector or vector for ets-2 (either 100 or 500 ng) as indicated, were co-transfected. Relative luciferase activity, adjusted for the internal
control and for protein concentration of the cell-free extracts, is presented. C, MCF-7 cells were transfected with either 5 g of BRCA1 promoter
luciferase reporter containing the wild-type ets-binding site (BRCA1) or the mutated ets-binding site M1  M2 (MT-BRCA1, see panel A), with
internal control as above, and with or without the addition of ets-2 expression vector (either 100 or 500 ng) as indicated. The activity is expressed
as fold-repression, which is, the ratio of relative luciferase activity for the BRCA1 or MT-BRCA1 reporter alone (with empty expression vector) to
the relative luciferase activity in the presence of ets-2. D, MCF-7 cells were transfected with 5 g of human BRCA1 or mouse MMP14 luciferase
reporters, internal control, and with or without mutated ets-2 T72A expression vector (either 100 or 500 ng) as indicated. Relative luciferase
activity, as above, is presented. For panels B–D, the average of three independent experiments performed in duplicate are presented. Error bars
indicate the standard deviation obtained from the three independent experiments.
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cell culture media (26). The results with one cloned cell line,
MCF-7 clone 21B, are presented in Fig. 3.
After growing cells in the absence of tetracycline for 0, 1, 8,
and 24 h, cell lysates were subjected to Western analysis using
the anti-HA epitope tag antibody. HA-ets-2 could be detected
1 h after stimulation, and expression levels were maximal
following 24 h of induction (Fig. 3A, first lane). The phospho-
rylated pT72 form of HA-ets-2 was present (Fig. 3A, second
lane) but the levels of the pT72 form were estimated to be
5–10% of the total ets-2 pool, significantly lower than in
MDA231 cells (see Fig. 1). The level of expression of endoge-
nous ets-2 remained low in the cells following induction of the
HA-ets-2 protein (Fig. 3A, third lane).
The expression of BRCA1, uPA, and MMP3 mRNA was stud-
ied by Northern analysis in the tetracycline-regulated cell line
(Fig. 3B). Induction of HA-ets-2 repressed BRCA1 mRNA levels
5-fold (Fig. 3B, lane 1), to a level similar to the level of expres-
sion observed in MDA231 cells (compare lanes 5 and 6). In
contrast, the expression of uPA mRNA and MMP3 mRNA
levels were increased 4–5-fold following induction of HA-
ets-2 expression (Fig. 3B, lanes 2 and 3, respectively). However,
the levels of uPA and MMP3 RNA induced demonstrated that
levels of expression were approximately still 5-fold lower than
in MDA231 cells (compare lanes 5 and 6), consistent with the
lower levels of phosphorylated ets-2 expressed in the tetracy-
cline-regulated MCF-7 cell line. Similar results were obtained
for all 4 genes studied with an independent cell clone that
expressed 3-fold lower levels of ets-2 than clone 21B (data not
shown).
The ets-2 Pointed Domain Interacts with Distinct Sets of
Nuclear Proteins in a Phosphorylation-dependent Manner—
The results presented above indicated that ets-2 could act as
both a repressor and activator of gene expression. We postu-
lated that ets-2 might interact with both co-repressors and
co-activators via the conserved pointed domain.
To begin testing this hypothesis, NIH 3T3 cells were con-
structed that expressed the HA-tagged ets-2 T72A mutation.
As shown in Fig. 2D, this mutated from of ets-2 could act as a
repressor but was only a weak activator, and thus we might
expect ets-2 T72A to interact preferentially with co-repressors.
Cells that expressed ets-2 T72A (Fig. 4A, lanes 3 and 4) were
compared with serum-starved NIH 3T3 cells that also have a
low level of the phosphorylated form of ets-2 (5, 6) (Fig. 4A,
lanes 1 and 2). Extracts from cells labeled with [35S]methionine
were lysed and immunoprecipitated under native conditions
with antibody specific for ets-2 (Fig. 4A, lanes 1 and 3) or for the
HA tag (Fig. 4A, lanes 2 and 4). In preliminary experiments the
positions of ets-2 and HA-ets-2 proteins, indicated by arrow-
heads in the figure, were determined in the denaturing gels by
Western blotting; the positions of authentic proteins were sub-
sequently confirmed by comparing their mobility with the mo-
bility of ets-2 and HA-ets-2 proteins overexpressed in COS cells
and run on the same gels (data not shown).
These immunoprecipitation experiments demonstrated that
the HA-tagged T72A version of ets-2 was expressed at the same
level as endogenous protein (Fig. 4A, arrowheads). Addition-
ally, several other proteins were reproducibly present in both
immunoprecipitates, in particular species of apparent molecu-
lar mass 200 and 50 kDa (p200 and p50, indicated by arrows in
Fig. 4A, lanes 3 and 4). These proteins were also detected in
ets-2 immunoprecipitates obtained serum-starved NIH 3T3
cells (Fig. 4A, lane 1).
In contrast, these bands were not detected in HA immuno-
precipitates prepared from NIH 3T3 cells (Fig. 4A, lane 1).
Furthermore, when the immunoprecipitation was performed
with higher salt concentration and inclusion of an ionic deter-
gent, these bands are no longer contained in the ets-2 or HA-
ets-2 immunoprecipitates (Fig. 4B). These control experiments
indicate that the p200 and p50 bands are present in a complex
with either endogenous or HA forms of ets-2, and are not likely
to be nonspecific or cross-reacting proteins found in the
immunoprecipitates.
In a complementary biochemical approach a recombinant
ets-2 protein, corresponding to the pointed domain (amino ac-
ids 67–170) that includes residue threonine 72 (5, 6), was
overexpressed in E. coli and covalently linked to an Affi-Gel 10
matrix. Whole cell lysates prepared from [35S]methionine-la-
beled NIH 3T3 cells were incubated with the ets-2 affinity
column. After washing, the proteins that bound to the column
were eluted and analyzed by SDS-PAGE along with the immu-
noprecipitated proteins (Fig. 4A, lane 5). The experiment dem-
onstrated that proteins with the same mobility as those de-
tected in the HA immunoprecipitate, in particular p200 and
p50, also bound to the ets-2 pointed domain affinity column.
The results support the conclusion that these proteins form a
specific complex with ets-2.
In a parallel experiment, the ets-2 affinity column was first
incubated with recombinant, active MAPK p42 to phosphoryl-
ate threonine 72. Previous studies demonstrated that threo-
nine 72 is the only site in the recombinant protein phosphoryl-
ated by MAPKs (5, 6). By using a trace amount of [-32P]ATP in
the kinase reaction, we were able to calculate that 90% of the
covalently linked ets-2 protein was phosphorylated (data not
shown). Analysis of proteins from NIH 3T3 cells that bound to
the phospho-ets-2 affinity column indicated that a discrete set
of proteins distinct from those bound to the unphosphorylated
column were detected (Fig. 4A, lane 6). Notably, p200 and p50
did not bind to the phospho-ets-2 column (Fig. 4A, lane 5 versus
lane 6).
To determine whether the phosphorylation of ets-2 in vivo
could affect interaction with the p200 and p50 proteins, immu-
noprecipitations were performed in ER-Raf/3T3 cells (6). These
cells contain an estrogen responsive form of the activated Raf
oncogene, and estrogen treatment persistently stimulates
MAPK kinases activity and ets-2 phosphorylation at Thr-72, as
well as ets-target gene activation (6). In these experiments, the
p200 and p50 proteins could again be co-immunoprecipitated
with endogenous ets-2, but stimulation of Raf signaling had no
significant effect on the relative amount of these proteins found
FIG. 3. Conditional expression of Ets-2 alters target gene ex-
pression in MCF-7 cells. A, after growing MCF-7/tetracycline activa-
tor cells in the absence of tetracycline (Tet) for 0, 1, 8, and 24 h, as
indicated, equal amounts of cell lysates were analyzed by SDS-PAGE,
followed by Western blot with the anti-HA antibody (top panel), the
anti-pT72 ets-2 (middle panel), or with an ets-2 non-discriminating
antibody (lower panel). Arrows indicate the position of ets-2. B, total
RNA was prepared from cells treated as in panel A, and analyzed by
Northern blotting (10 g/lane) with probes specific for BRCA1, uPA,
MMP3, and -actin, as indicated.
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in the immunoprecipitates (Fig. 4C, lane 1 compared with lane
2). Western analysis of a portion of these immunoprecipitates
demonstrated that phosphorylated ets-2 could be detected fol-
lowing activation of Raf (Fig. 4C, lower panels). We estimated
that about 50–60% of ets-2 was phosphorylated at position
Thr-72 in the experiment shown (see “Experimental Proce-
dures”). Thus, a significant pool of unphosphorylated ets-2 was
present in the cells and immunoprecipitates analyzed in this
experiment.
Ets-2 Co-immunoprecipitates with Brg-1 and Components of
the Mammalian SWI/SNF Complex—As a first attempt at
identifying the proteins that co-immunoprecipitated with ets-2,
we took a candidate protein approach and obtained antibodies
for known co-activators and co-repressors in the 200-kDa size
range. Fortuitously, one of the first antibodies tested was di-
rected against Brg-1, the ATPase hydrolyzing subunit of the
mSWI/SNF complex (13, 14), and recognized the p200 protein
(Fig. 5A). In addition, antibody against the BAF-57/p50 subunit
of the mSWI/SNF complex (13) recognized the p50 protein
present in anti-ets-2 immunoprecipitates (Fig. 5A). The Ini1
subunit of mSWI/SNF (12–14) could also be detected in a com-
plex with ets-2 in NIH 3T3 cells (Fig. 5A). In contrast, the
Brm-1 protein, a protein highly related to Brg-1 that can be
found in a distinct mSWI/SNF complex (13, 14), was not im-
munoprecipitated with ets-2 (Fig. 5A).
The MCF-7 cells engineered to conditionally express ets-2 were
used to determine whether the ets-2/mSWI/SNF interaction
could be detected in human cells (Fig. 5B). For these experi-
ments, cells were grown for 8 h after removing tetracycline from
the culture media followed by isolation of ets-2 complexes by
immunoprecipitation. These experiments showed that Brg-1 and
Ini1 could be detected in complex with ets-2 after tetracycline
removal, but not in cells maintained in tetracycline (Fig. 5B). The
BAF157/p50 antibody did not cross-react with proteins present in
MCF-7 cells in our hands (data not shown).
The ets-2 Pointed Domain Forms a Phosphorylation-depend-
ent Complex with Brg-1 in Vitro—To determine whether the
interaction of Brg-1 with ets-2 was direct and dependent on
ets-2 phosphorylation, GST pull-down experiments were per-
FIG. 4. Ets-2 interacts with nuclear proteins in a phosphorylation-dependent manner. A, serum-starved NIH 3T3 cells (lanes 1 and 2),
or NIH 3T3 cells that expressed HA-tagged Ala-72 ets-2 (lanes 3 and 4) were labeled with [35S]methionine and protein extracts were prepared. The
labeled extracts were incubated with either an ets-2 specific antibody (E2, lanes 1 and 3) or with the anti-HA antibody (HA, lanes 2 and 4). In
parallel experiments, labeled NIH 3T3 extracts were incubated with an ets-2 pointed domain affinity column that was either unphosphorylated
(lane 5) or phosphorylated by MAPK p42 (lane 6). Proteins present in the immunoprecipitates or bound to the affinity column were separated by
SDS-PAGE and visualized by autoradiography. The position of ets-2 proteins (endogenous and HA-tagged, determined by Western blotting) are
indicated by arrowheads, and co-immunoprecipitated proteins of relative mass 200 and 50 kDa are indicated by arrows. Note that the band with
similar mobility to HA-ets-2 in lanes 5 and 6 does not cross-react with the HA or ets-2 antibodies. The position of molecular weight markers are
also indicated in the figure. B, immunoprecipitation as in panel A, using ets-2 and HA antibodies as indicated. NIH 3T3 extracts were in lanes 1
and 3, whereas extracts from cells expressing HA-ets T72A were in lanes 2 and 4. Lanes 1 and 2 were performed under standard conditions (150
mM NaCl and 1% Nonidet P-40), whereas lanes 3 and 4 were performed with more stringent conditions (500 mM NaCl and 0.5% deoxycholate). C,
immunoprecipitation as in panel A, using ets-2 antibody and labeled extracts prepared from ER-Raf/NIH 3T3 cells (6) grown in the absence (lane
1) or presence of 106 M -estradiol (lane 2). Position of endogenous ets-2 is indicated by the arrowhead, whereas the p200 and p50 bands are shown
by arrows. The lower panels show the results of Western blotting with these cells, using pT72 or non-discriminating ets-2 antibody, as indicated.
FIG. 5. Ets-2 forms a complex with components of mammalian
SWI/SNF. Panel A, Western analysis of proteins that co-immunopre-
cipitate with HA-ets-2 Ala-72 in NIH 3T3 cells that express this exog-
enous form of ets-2 (lane 2). Components of the mSWI/SNF complex,
Brg-1, BAF57/p50, and Ini1, all were found in complex with the HA-
ets-2 T72A (panels 1–3), but Brm-1 is not found in the complex (lane 2,
panel 4). Lane 1 is a Western blot performed on total nuclear extracts
prepared from these cells. As a control, immunoprecipitations with HA
antibody were performed on normal NIH 3T3 cells that do not express
the HA-tagged protein (lane 3). Panel B, Western analysis of proteins
that co-immunoprecipitated with HA-ets-2 in the tetracycline-off
MCF-7 cells (see Fig. 3). Tetracycline was removed from cells for 8 h,
HA-ets-2 was immunoprecipitated with HA antibody, and the immuno-
precipitates were analyzed by Western blots with antibodies as indi-
cated (lane 3). Lane 1 represents Western analysis of crude nuclear
extracts with the same antibody, whereas lane 2 is a Western blot
performed on material in the HA immunoprecipitate prepared from
cells grown in the presence of tetracycline (non-inducing conditions).
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formed. A recombinant GST-Brg-1 fusion protein containing
the entire C-terminal portion of the protein from amino acids
1108 to 1686 was used in “pull-down” assays with the recom-
binant ets-2 pointed region (Fig. 6A). In these experiments,
GST-Brg-1 could form a complex with the ets-2 pointed protein,
whereas GST alone did not (Fig. 6A, top panel, lane 2 versus
lane 1). Approximately 30% of the ets-2 input was present in
the complex (lane 3 represents 50% of ets-2 input).
In a parallel experiment, the ets-2 pointed region was phos-
phorylated in vitro using recombinant MAPK p42 and
[-32P]ATP. Cold ATP was not added to the kinase reaction, so
that only a trace amount of the ets-2 pointed protein would be
phosphorylated. The 32P-labeled ets-2 pointed protein was used
in the pull-down assay with GST-Brg-1 as above (Fig. 6B). In
this case, less than 5% of the 32P-labeled ets-2 protein was
found in a complex with the GST-Brg-1 protein (Fig. 6B, top
panel, lane 2 versus lane 3). In contrast, Western analysis
demonstrated that30% of the unlabeled ets-2 pointed domain
could still be detected in the pull-down fraction.
Brg-1 and ets-2 Repress the BRCA1 Promoter in SW13
Cells—To test the functional significance of the Brg-1/ets-2
interaction, the effects of these nuclear factors on the activity of
the BRCA1-luciferase reporter were studied (Fig. 7). For these
experiments, the tumor cell line SW13, which lacks detectable
Brg-1 and Brm-1 proteins (15, 16, 37), was used. First, the
BRCA1-luciferase reporter was introduced into cells with the
combination of expression vectors for ets-2 and Brg-1 in tran-
sient transfection assays (Fig. 7A, left panel). The results of the
experiments, expressed as fold-repression, indicated that nei-
ther expression vectors for ets-2 nor Brg-1 alone repressed the
BRCA1 reporter. However, the combination of the two resulted
in an approximate 3-fold repression of reporter activity (Fig.
7A, left panel). If an expression vector for a Brg-1 gene encoding
a protein with a mutation in the ATP-binding domain, Brg-1
(K798R), was used in the assay, repression of the BRCA1
reporter was not observed in either the presence or absence of
ets-2 (Fig. 7A, left panel). As a control, we also studied the
ability of Brg-1 to act as a co-activator for the glucocorticoid
receptor (GR) using an artificial glucocorticoid responsive re-
porter that contained 8 GR-binding sites. As previously re-
ported, the combination of Brg-1 and GR expression vectors
could stimulate a target reporter more efficiently than either
gene alone (16) (Fig. 7A, right panel).
Because transient DNA templates may not always be orga-
nized as chromatin (16, 38), we also performed assays with
SW13 cells that contained stably integrated BRCA1-luciferase
reporter genes (Fig. 7B). In these experiments, ets-2 expression
by itself had little effect on the reporter activity. Brg-1 expres-
sion alone could repress the BRCA1 reporter 7-fold, whereas
the combination of ets-2 and Brg-1 resulted in a further dose-
dependent repression of BRCA1 promoter activity (Fig. 7B). A
14-fold reduction was observed with the higher concentration of
ets-2 expression vector. As in the transient assays, Brg-1
(K798R) did not repress BRCA1 reporter activity alone or in
combination with ets-2.
DISCUSSION
Ets-2 has previously been characterized as an activator of
gene expression, and the results presented here indicate that
this factor can also act as a repressor. Results from transient
transfection assays and following conditional expression of
FIG. 6. Phosphorylation-dependent direct interaction be-
tween Brg-1 and Ets-2 in vitro. A, recombinant GST-Brg-1 (1 g) was
immobilized on GST beads and then incubated with the recombinant,
unphosphorylated pointed domain of ets-2 (1 g). Protein bound to
beads was analyzed by SDS-PAGE and Western blotting, using ets-2 or
Brg-1 specific antibodies as indicated. Lane 1, GST only ets-2 pointed;
lane 2, GST-Brg-1  unphosphorylated ets-2; lane 3, 50% of input of
ets-2 and Brg-1. B, pull-down assay with GST-Brg-1 and ets-2 pointed
phosphorylated by Erk using [-32P]ATP. Upper panel is an autoradio-
graph to detect 32P-labeled ets-2 pointed. Radioactivity was quantified
using a Amersham Biosciences PhosphorImager. Two lower panels are
Western blots probed with Brg-1 and ets-2 antibodies, respectively.
Lane 1, GST only  ets-2 pointed; lane 2, GST-Brg-1  32P-labeled
ets-2; lane 3, 50% of input of ets-2 and Brg-1.
FIG. 7. Brg-1 and ets-2 repress BRCA1 promoter reporter in
SW13 cells. A, transient transfections performed in SW13 cells. 5 g of
human BRCA1-luciferase reporter was co-transfected with 100 ng of
expression vector for ets-2 and 250 ng of expression vector for Brg-1, or
Brg-1 K798R, or with a combination of 100 ng of ets-2 vector and 250 ng
of Brg-1, or Brg-1 K798R vectors, as indicated (left bar graph). In
parallel experiments shown in the bar graph to the right, 5 g of an 8
GRE reporter was co-transfected with 100 ng of rat GR expression
vector (47), 250 ng of expression vector for Brg-1, or with a combination
of 100 ng of GR vector and 250 ng of Brg-1 vector. All experiments were
performed in the presence of 107 M dexamethasone in this analysis.
Fold-induction indicates the ratio of 8  GRE relative activity alone
compared with activity seen with GR or Brg-1 alone, or a combination
of the two. B, transfection with stably integrated BRCA1-luciferase
reporter. For these experiments, 1 g of Brg-1 or Brg-1 K798R alone or
in combination with ets-2 (0.2 or 1 g, as indicated) were transfected
into SW13 cells that contained stably integrated copies of the BRCA1-
luciferase reporter. For both panels A and B, fold-repression is the ratio
of relative luciferase activity (see “Experimental Procedures”) for the
BRCA1-luciferase reporter alone (with empty expression vectors) to the
activity in the presence of ets-2, Brg-1 (Brg-1 K798R), or a combination
of both ets-2 and Brg-1 (Brg-1 K798R). Results of three independent
experiments performed in duplicate are presented. Error bars indicate
standard deviation of the measurements.
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ets-2 demonstrate that ets-2 could both repress and activate
target genes in MCF-7 cells. Furthermore, ets-2 directly inter-
acted with Brg-1, the ATPase component of the mSWI/SNF
complex, and Brg-1 behaved as a transcriptional co-repressor
along with ets-2. Specificity for target gene regulation within
the ets family of transcription factors can be achieved in part
through the ability of signaling pathways to selectively activate
ets family members (1). For example, the ras pathway selec-
tively activates only a subset of ets family members, including
ets-2. The results presented here may begin to provide insight
into how signaling pathways modulate the activity of ets-2.
At least in vitro, the pointed domain of ets-2 interacted with
distinct sets of cellular proteins, including Brg-1, dependent on
phosphorylation of residue threonine 72, a target of ras/MAPK
signaling. These results suggest the hypothesis that ras-de-
pendent phosphorylation of ets-2 switches the activity of this
factor from repressor to activator by modulating interactions
with co-repressors like Brg-1. However, the fact that pools of
both phosphorylated and non-phosphorylated ets-2 are present
even in cells that have high activation of the ras/raf/MAPK
signaling pathways as can be achieved with the ER-Raf system
(6), makes it difficult to determine in vivo whether phosphoryl-
ation of ets-2 strictly modulates its activity as repressor, or
even its interaction with Brg-1. Whereas the model that sig-
naling pathways can modulate the pools of ets-2 that act as
either repressor or activator within cells is attractive, addi-
tional work is required to validate this model. It is possible that
signaling pathways never lower the level of non-phosphoryl-
ated ets-2 sufficiently to affect repression of target genes. A
significant portion of ets-2 may always be present in a repres-
sor complex within cells, and phosphorylation may only in-
crease the pool of ets-2 that is able to activate target genes.
The results presented here provide further evidence that the
mammalian SWI/SNF complex can also repress gene expres-
sion, in addition to the well characterized role as a co-activator
in mammalian cells (13, 15, 16). At least two models can be
proposed to account for the activity of the ets-2Brg-1 complex
as a repressor instead of as an activator of gene expression. One
possibility is that direct interaction with ets-2 may cause a
conformational change in the mSNF/SWI complex resulting in
an increased ability to form closed nucleosome structures over
the open, altered nucleosome structure (14).
A second possibility that may account for our results is that
distinct subcomplexes may mediate activation and repression
functions of mSWI/SNF (20, 39). In mammalian cells, discrete
Brg-1 and Brm-1 subcomplexes containing mSin3 co-repressors
have been characterized (39), whereas recent work in yeast sug-
gests that the co-repressor function may be mediated by the
ATPase-hydrolyzing SNF2 subunit alone, and not require addi-
tional complex subunits (20). Our analysis indicates that at least
two known components of mSWI/SNF (Ini1 and BAF57/p50) in
addition to Brg-1 are present in the putative ets-2 co-repressor
complex. The closely related gene product Brm-1 could not be
detected in a complex with ets-2, consistent with evidence sug-
gesting that Brg-1 and Brm-1 complexes are biochemically and
functionally distinct (39, 40). However, additional antibodies that
are available for mSWI/SNF complex subunits, for example, p155
and p170, were not sufficiently specific, at least in our hands, to
allow us to determine with certainty whether other components
were associated with ets-2. Defining the exact composition of the
complex, and demonstrating that the ets-2 containing complex
has chromatin remodeling activity, are important questions that
need to be addressed by future work.
New mechanisms by which the tumor suppressor BRCA1
might be down-regulated in mammary tumor cells are biolog-
ically significant. Germline mutations in BRCA1 account for
approximately one-half of inherited breast cancers, but muta-
tions of BRCA1 are infrequent in sporadic breast cancer (41).
Several studies indicate that BRCA1 expression is down-regu-
lated in primary breast tumors versus normal breast tissue
(42–45). Aberrant methylation of CpG islands in the BRCA1
promoter may be one mechanism that leads to decreased gene
expression in sporadic breast cancer (42–44). However, hyper-
methylation of the BRCA1 promoter region is only found in
13% of sporadic breast cancer cases (46), suggesting that
additional mechanisms may be involved in BRCA1 silencing.
Ets-2 as both a repressor of BRCA1 and an activator of extra-
cellular proteases like uPA, MMP3, and MMP14 in a subset of
breast cancer cases provides an attractive model.
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